Title 42 — The Public Health and Welfare
Part B · Chapter 6A — Public Health Service
§ 284q. Pain research
Statutory text
Research initiatives
In general
The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain.
Annual recommendations
Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 282a(c)(1) of this title for the Common Fund or otherwise available for such initiatives.
Definition
In this subsection, the term “Pain Consortium” means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection.
Interagency Pain Research Coordinating Committee
Establishment
The Secretary shall establish not later than 1 year after , and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the “Committee”), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research.
Membership
In general
The Committee shall be composed of the following voting members:
Not more than 7 voting Federal representatives appoint 1 by the Secretary from agencies that conduct pain care research and treatment.
12 additional voting members appointed under subparagraph (B).
Additional members
The Committee shall include additional voting members appointed by the Secretary as follows:
6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals.
6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.
Nonvoting members
The Committee shall include such nonvoting members as the Secretary determines to be appropriate.
Chairperson
The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH.
Meetings
The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year.
Duties
The Committee shall—
develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration;
identify critical gaps in basic and clinical research on—
the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain;
the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and
risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and
make recommendations to the Director of NIH—
to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;
on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and
on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.
Report
The Secretary shall ensure that recommendations and actions taken by the Director with respect to the topics discussed at the meetings described in paragraph (4) are included in appropriate reports to Congress.
Review
The Secretary shall review the necessity of the Committee at least once every 2 years.
Footnotes
- 1 So in original. Probably should be “appointed”.
Legislative history
Reconstructed from this section’s Code source credit and amendment notes, resolved against the local Statutes at Large. Editorial notes are evidence, not the law that made the change.
Patient Protection and Affordable Care Act
Pub. L. 111–148 title IV § 4305(b) · 124 Stat. 119
Enacted · 42 U.S.C. § 284q
July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), Mar. 23, 2010, 124 Stat. 585
Source evidence
Code source credit
July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), Mar. 23, 2010, 124 Stat. 585Enacted provision · exact public law section
(b) Pain Research at National Institutes of Health.— Part B of title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by adding at the end the following: “SEC. 409J. PAIN RESEARCH. “(a) Research Initiatives.— “(1) In general.— The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain. “(2) Annual recommendations.— Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 402A(c)(1) for the Common Fund or otherwise available for such initiatives. “(3) Definition.— In this subsection, the term ‘Pain Consortium’ means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection. “(b) Interagency Pain Research Coordinating Committee.— “(1) Establishment.— The Deadline. Secretary shall establish not later than 1 year after the date of the enactment of this section and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the ‘Committee’), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research. “(2) Membership.— “(A) In general.— The Committee shall be composed of the following voting members: “(i) Not more than 7 voting Federal representatives appoint by the Secretary from agencies that conduct pain care research and treatment. “(ii) 12 additional voting members appointed under subparagraph (B). “(B) Additional members.— The Committee shall include additional voting members appointed by the Secretary as follows: “(i) 6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals. “(ii) 6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions. “(C) Nonvoting members.— The Committee shall include such nonvoting members as the Secretary determines to be appropriate. “(3) Chairperson.— The voting members of the Committee shall select a chairperson from among such members. The selection of a chairperson shall be subject to the approval of the Director of NIH. “(4) Meetings.— The Committee shall meet at the call of the chairperson of the Committee or upon the request of the Director of NIH, but in no case less often than once each year. “(5) Duties.— The Committee shall— “(A) develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, and treatment of pain and diseases and disorders associated with pain; “(B) identify critical gaps in basic and clinical research on the symptoms and causes of pain; “(C) make recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; “(D) make recommendations on how best to disseminate information on pain care; and “(E) make recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research. “(6) Review.— The Secretary shall review the necessity of the Committee at least once every 2 years.” .Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act
Pub. L. 115–271 § 7042(1)(A) · 132 Stat. 3894
Substituted · 42 U.S.C. § 284q(b)(5)(A)
Pub. L. 115–271, § 7042(1)(A), substituted “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration” for “and treatment of pain and diseases and disorders associated with pain”
Source evidence
Code amendment note
Subsec. (b)(5)(A). Pub. L. 115–271, § 7042(1)(A), substituted “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration” for “and treatment of pain and diseases and disorders associated with pain”.Enacted provision · exact public law section
(A) in subparagraph (A), by striking “and treatment of pain and diseases and disorders associated with pain” and inserting “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration”;Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act
Pub. L. 115–271 § 7042(1)(B) · 132 Stat. 3894
Substituted · 42 U.S.C. § 284q(b)(5)(B)
Pub. L. 115–271, § 7042(1)(B), substituted “on—” and cls. (i) to (iii) for “on the symptoms and causes of pain;”
Source evidence
Code amendment note
Subsec. (b)(5)(B). Pub. L. 115–271, § 7042(1)(B), substituted “on—” and cls. (i) to (iii) for “on the symptoms and causes of pain;”.Enacted provision · exact public law section
(B) in subparagraph (B), by striking “on the symptoms and causes of pain;” and inserting the following: “on— “(i) the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain; “(ii) the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and “(iii) risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and” ; andSubstance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act
Pub. L. 115–271 § 7042(1)(C) · 132 Stat. 3894
Added · 42 U.S.C. § 284q(b)(5)(C)(E)
Pub. L. 115–271, § 7042(1)(C), added subpar. (C)
Struck · 42 U.S.C. § 284q(b)(5)(C)(E)
Pub. L. 115–271, § 7042(1)(C), struck out former subpars. (C) to (E) which read as follows:
Source evidence
Code amendment note
Subsec. (b)(5)(C) to (E). Pub. L. 115–271, § 7042(1)(C), added subpar. (C) and struck out former subpars. (C) to (E) which read as follows:“(C) make recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; “(D) make recommendations on how best to disseminate information on pain care; and “(E) make recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.”
Enacted provision · exact public law section
(C) by striking subparagraphs (C) through (E) and inserting the following: “(C) make recommendations to the Director of NIH— “(i) to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; “(ii) on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and “(iii) on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.” ;Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act
Pub. L. 115–271 § 7042(2) · 132 Stat. 3894
Added · 42 U.S.C. § 284q(b)(6); 42 U.S.C. § 284q(b)(7)
Pub. L. 115–271, § 7042(2), (3), added par. (6)
Redesignated · 42 U.S.C. § 284q(b)(6); 42 U.S.C. § 284q(b)(7)
Pub. L. 115–271, § 7042(2), (3), redesignated former par. (6) as (7)
Source evidence
Code amendment note
Subsec. (b)(6), (7). Pub. L. 115–271, § 7042(2), (3), added par. (6) and redesignated former par. (6) as (7).Enacted provision · exact public law section
(2) by redesignating paragraph (6) as paragraph (7); and
7 of 7 references resolved to an enrolled provision
Editorial Notes
Amendments
2018—Subsec. (b)(5)(A). Pub. L. 115–271, § 7042(1)(A), substituted “treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration” for “and treatment of pain and diseases and disorders associated with pain”.
Subsec. (b)(5)(B). Pub. L. 115–271, § 7042(1)(B), substituted “on—” and cls. (i) to (iii) for “on the symptoms and causes of pain;”.
Subsec. (b)(5)(C) to (E). Pub. L. 115–271, § 7042(1)(C), added subpar. (C) and struck out former subpars. (C) to (E) which read as follows:
“(C) make recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;
“(D) make recommendations on how best to disseminate information on pain care; and
“(E) make recommendations on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.”
Subsec. (b)(6), (7). Pub. L. 115–271, § 7042(2), (3), added par. (6) and redesignated former par. (6) as (7).
Credits
1944–2018 · 2 acts
- 1944July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), , 124 Stat. 585
- 2018amended Pub. L. 115–271, title VII, § 7042, , 132 Stat. 4016.
Show as published
(July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), , 124 Stat. 585; amended Pub. L. 115–271, title VII, § 7042, , 132 Stat. 4016.)